Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | TACR1 | P25103 | 1/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | RORC | P51449 | 3/20 | 0.40 |
| ▸ | JAK1 | P23458 | 2/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.39 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.38 |
| ▸ | MMP13 | P45452 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | STS | P08842 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL646451 | 0.88 | MAPT (0.47) | MAPTTACR1GPR119HPGDSMN1; SMN2 | |
| SCHEMBL29716454 | 0.82 | KMT2A (0.50) | MAPTTACR1ALDH1A1 | |
| SCHEMBL1282206 | 0.81 | SMN1; SMN2 (0.42) | TACR1HPGDSMN1; SMN2ALDH1A1 | |
| SCHEMBL2206945 | 0.76 | SMN1; SMN2 (0.46) | GPR119HPGDSMN1; SMN2ALDH1A1 | |
| SCHEMBL5012787 | 0.75 | MAPT (0.51) | MAPTTACR1GPR119RORCJAK1 | |
| SCHEMBL5562721 | 0.75 | MAPT (0.41) | MAPTTACR1GPR119HPGDSMN1; SMN2 | |
| SCHEMBL6795066 | 0.74 | MAPT (0.55) | MAPTTACR1GPR119RORCSTS | |
| SCHEMBL24484249 | 0.74 | MAPT (0.52) | MAPTTACR1GPR119RORCJAK1 | |
| SCHEMBL619446 | 0.73 | SMN1; SMN2 (0.44) | TACR1HPGDSMN1; SMN2ALDH1A1 | |
| SCHEMBL21777896 | 0.72 | MAPT (0.46) | MAPTTACR1GPR119HPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8119563-B2 | N-substituted azacycles | FMC CORPORATION (US) | 2012-02-21 | — | — | US | disclosed |
| US-8119563-B2 | N-substituted azacycles | FMC CORPORATION (US) | 2012-02-21 | — | — | US | disclosed |
| US-20090215821-A1 | N-Substituted Azacycles | FMC CORPORATION | 2009-08-27 | — | — | US | disclosed |
| US-20090215821-A1 | N-Substituted Azacycles | FMC CORPORATION | 2009-08-27 | — | — | US | disclosed |
| EP-1673083-A4 | N-SUBSTITUTED AZACYCLES | BAYER CROPSCIENCE AG (DE) | 2008-12-17 | — | — | EP | disclosed |
| EP-1673083-A2 | N-SUBSTITUTED AZACYCLES | FMC CORPORATION (US) | 2006-06-28 | — | — | EP | disclosed |
| WO-2005036961-A2 | N-SUBSTITUTED AZACYCLES | FMC CORPORATION (US) | 2005-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215821-A1 | N-Substituted Azacycles | DDT, UQCRB, DNMT1 | MAPT 4642/4885TACR1 321/4885GPR119 777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.